Hopes have risen for a new treatment for severe childhood epilepsy Dravet syndrome, on the back of new data for Biogen and Stoke's zorevunersen ...

In February 2025, Biogen Inc. (NASDAQ:BIIB) formed a partnership with Stoke Therapeutics to develop zorevunersen for Dravet ...

Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by severe, recurrent seizures as well as significant cognitive and behavioral impairments.

The zorevunersen data give us early evidence that this new genetically-targeted approach could address the underlying cause of Dravet syndrome, resulting in additional seizure control and offer ...

Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) that is characterized by severe, recurrent seizures as well as significant cognitive and behavioral impairments. There are ...

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS ...

However, research has shown that controlled use of the drug is effective in treating Dravet Syndrome and Lennox-Gastaut Syndrome, rare forms of epilepsy otherwise difficult to treat, she said. Since ...

The Stanley Brothers created Charlotte's Web, the CBD supplement that’s worked wonders on seizures. Now they are developing pharmaceuticals derived from cannabis and psilocybin with hopes of ...